Cytosorbents Corporation (NASDAQ:CTSO):
CytoSorbents Awarded Approximately $1.0 Million in Phase II SBIR Funding to Optimize New Treatment Approaches for Severe Hyperkalemia.
The company is unchanged since yesterday’s close of $6.15.
CytoSorbents Corporation, launched on April 25, 2002, is a critical care focused immunotherapy company. The Company is involved in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Business’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Business’s CytoSorb is an extracorporeal cytokine filter and is designed to reduce the cytokine storm that causes inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury and pancreatitis. In addition, CytoSorb is used in other inflammatory conditions, such as cardiac surgery, autoimmune disease flares, cancer, cytokine release syndrome in cancer immunotherapy and cancer cachexia..
Company shares last traded at $6.15 a bit higher than the 50 day moving average of $5.93 and which is quite a bit above the 200 day moving average of $4.98. The 50 day moving average was up by +3.65% and the 200 day average was up $1.17.
In the last earnings report the EPS was $-0.37 and is projected to be $-0.27 for the current year with 28,133,000 shares presently outstanding. Analysts expect next quarter’s EPS to be $-0.11 with next year’s EPS projected to be $-0.28.
Investors are feeling more bearish on shares of the company if you take note of the uptick in short interest. The firm recorded a rise in short interest of 3.95% between September 29, 2017 and October 13, 2017. Short interest grew from 1,194,410 to 1,241,638 over that timeframe. Days to cover decreased 0.0 to 6.0 and the percentage of shorted shares was 0.04% on October 13.